FDA approves Wegovy weight-loss pill from Novo Nordisk [USA TODAY]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: USA TODAY
President Donald Trump announces discounted pricing for Zepbound and Wegovy and expanding Medicare coverage so more people can access the drugs. The once-daily tablet — called the Wegovy pill — is the first oral version of glucagon-like peptide-1 drugs, or GLP-1s, Novo Nordisk said in a news release. The drugs were first used to treat diabetes but have since been approved for obesity, which has dramatically expanded the patient pool. The pill is 25 milligrams of semaglutide, the same active ingredient in injectable Wegovy and Ozempic. The pill was approved for chronic weight management in adults with obesity or overweight and at least one related health condition. "Wegovy pill is the next chapter in our decades-long GLP-1 experience—supported by the most affordable self-pay price to date in a GLP-1 for obesity," Dave Moore, executive vice president of U.S. Operations at Novo Nordisk, said in a statement. "We are prepared?for a full US launch in?early January 2026,?with?manufact
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk [MSNBC.com]MSNBC.com
- FDA approves Wegovy pill for weight loss, the first daily oral medication of its kind [CBS News]CBS News
- FDA approves Wegovy weight loss pill from Novo Nordisk [MSNBC.com]MSNBC.com
- US regulators approve Wegovy pill for weight loss [Yahoo! Finance Canada]Yahoo! Finance Canada
- US Approves First GLP-1 Pill For Weight Loss: Novo Nordisk [Barron's]Barrons
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website